ArticleAnnals of translational medicine2019
Pre-treatment systemic immune-inflammation represents a prognostic factor in patients with advanced non-small cell lung cancer.
Article in Annals of translational medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prognostic Significance of the Systemic Immune-Inflammation Index (SII) in Patients With Small Cell Lung Cancer: A Meta-Analysis.Frontiers in oncology · 2022Pooled it
- The Association Between Inflammatory Scores and Frailty Severity: An Exploratory Retrospective Analysis in Non-Small-Cell Lung Cancer Surgical Patients.Medical sciences (Basel, Switzerland) · 2026Article
- Inflammation-Related Parameters in Lung Cancer Patients Followed in the Intensive Care Unit.Healthcare (Basel, Switzerland) · 2025Article
- Relationship between systemic immune-inflammation index and all-cause mortality in stages IIIB-IV epidermal growth factor receptor-mutated lung adenocarcinoma.Frontiers in endocrinology · 2025Article
- Radiomicsmetabolic signature profiles for advanced non-small cell lung cancer with chemoimmunotherapy by reflecting biological function and survival.Translational lung cancer research · 2024Article
- Prognostic significance of systemic immune inflammatory index in NSCLC: a meta-analysis.Lung cancer management · 2024Review
- The Prognostic Value of Systemic Immune-Inflammation Index Supporting Age-Adjusted Charlson Comorbidity Index in Non-Small Cell Lung Cancer Patients with First-Line Platinum-Based Chemotherapy.International journal of general medicine · 2024Article
- Targeting Inflammation in Non-Small Cell Lung Cancer through Drug Repurposing.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Biomarkers of systemic inflammation predict survival with first-line immune checkpoint inhibitors in non-small-cell lung cancer.ESMO open · 2022Article
- The Relationship Between Systemic Immune Inflammatory Index and Prognosis of Patients With Non-Small Cell Lung Cancer: A Meta-Analysis and Systematic Review.Frontiers in surgery · 2022Review
- ComprehensiveFrontiers in immunology · 2022Article
- Pretreatment neutrophil-to-lymphocyte ratio as an important prognostic marker in stage III locally advanced non-small cell lung cancer: confirmatory results from the PROCLAIM phase III clinical trial.Journal of thoracic disease · 2021Article
- Systemic immune-inflammation index is a stage-dependent prognostic factor in patients with operable non-small cell lung cancer.Translational lung cancer research · 2021Article
- A nomogram to predict the overall survival of patients with symptomatic extensive-stage small cell lung cancer treated with thoracic radiotherapy.Translational lung cancer research · 2021Article
- Prognostic Impact of the Advanced Lung Cancer Inflammation Index (ALI) in Metastatic Non-Small Cell Lung Cancer Treated with First Line Chemotherapy.Asian Pacific journal of cancer prevention : APJCP · 2021Article
- Systemic inflammation is associated with inferior disease control and survival in stage III non-small cell lung cancer.Annals of translational medicine · 2021Article
- Systemic Immune-Inflammation Index Is a Prognostic Predictor in Patients with Intrahepatic Cholangiocarcinoma Undergoing Liver Transplantation.Mediators of inflammation · 2021Article
- Prognostic value of pre-treatment systemic immune-inflammation index in patients with endometrial cancer.PloS one · 2021Article
- Using the Systemic Immune-Inflammation Index (SII) as a Mid-Treatment Marker for Survival among Patients with Stage-III Locally Advanced Non-Small Cell Lung Cancer (NSCLC).International journal of environmental research and public health · 2020Article
- Systemic immune-inflammation index and prognosis of advanced non-small cell lung cancer.Annals of translational medicine · 2020Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInflammation plays an important role in pathogenesis, development and progression of lung cancer. The aim of the study is to assess the prognostic role of Systemic Immune-Inflammation Index (SII), obtained by analyzing the neutrophil, lymphocyte and platelet counts, and to design prognostic models for patients receiving first-line chemo- or targeted therapy for advanced non-small cell lung cancer (NSCLC).
methodsWe conducted an analysis on 311 patients with advanced NSCLC, treated with first line chemo- or targeted therapy till June 2015 at our Institution. Patients were stratified in two groups with SII ≥1,270 (Group A)
resultsAt baseline, 179 patients had SII ≥1,270 (Group A), whilst 132 had lower SII (Group B). The median OS was 12.4 months in Group A and 21.7 months in Group B (P<0.001), whilst the median PFS was 3.3 and 5.2 months, respectively (P=0.029). At multivariate analysis, male gender, ECOG-PS ≥2 and SII >1,270 were predictors of worst OS, whilst IV tumor stage was only slightly significant (P=0.08). Otherwise, only wild-type EGFR status and SII ≥1,270 were independent prognostic factors for worst PFS.
conclusionsPre-treatment SII is an independent prognostic factor for patients with advanced NSCLC treated with first-line therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.